Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

537

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Psoriasis
Interventions
DRUG

M518101

DRUG

Vehicle

Trial Locations (31)

18201

Derm Dox Center for Dermatology, Hazleton

19034

Philadelphia Institute of Dermatology, Fort Washington

27104

Wake Forest University, Winston-Salem

27518

PMG research of Raleigh, Cary

28401

Atlantic Dermatology Associates, Wilmington

29650

Radiant Research, Greer

32204

North Florida Dermatology Associates, Jacksonville

33027

FXM Research Miramar, Miramar

33144

International Dermatology Research Inc, Miami

33472

Visions Clinical Research, Boynton Beach

33609

Olympian Clinical Research, Tampa

33781

Belleair Research Center, Pinellas Park

34471

Renstar Medical Research, Ocala

36608

Coastal Clinical Research, Mobile

46168

The Indiana Clinical Trials Center, Plainfield

46256

Dawes Fretzin Clinical Research Group, Indianapolis

55432

Minnesota Clinical Study Center, Fridley

55435

Radiant Research, Edina

70605

Shondra Smith Dermatology & Advanced Aesthetics, Lake Charles

73104

Oklahoma University Health Science Center, Oklahoma City

77056

The Center for Skin Research, Houston

77494

Suzanne Bruce and Associates The Center for Skin Research, Katy

77598

Center for Clinical Studies, Webster

78229

Dermatology Clinical Res., San Antonio

85018

Omni Dermatology, Phoenix

92117

Skin Surgery Medical Group, San Diego

92123

University Clinical Trials, San Diego

98101

Dermatology Associates, Seattle

06511

The Savin Center, New Haven

02919

Clinical Partners, Johnston

02903

Rhode Island Hospital Dermatology, Providence

All Listed Sponsors
lead

Maruho North America Inc.

INDUSTRY

NCT01873677 - Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis | Biotech Hunter | Biotech Hunter